Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 1/20 | 0.39 |
| ▸ | MLNR | O43193 | 5/20 | 0.35 |
| ▸ | GLRA3 | O75311 | 1/20 | 0.34 |
| ▸ | GLRB | P48167 | 1/20 | 0.34 |
| ▸ | XIAP | P98170 | 2/20 | 0.33 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.33 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | PIM3 | Q86V86 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5823362 | 1.00 | HTR6 (0.39) | HTR6MLNRGLRA3GLRBXIAP | |
| SCHEMBL5807018 | 1.00 | HTR6 (0.39) | HTR6MLNRGLRA3GLRBXIAP | |
| Trifluoroacetic Acid SCHEMBL5817999 | 0.93 | HTR6 (0.35) | HTR6MLNRXIAPBIRC2KDM4E | |
| Trifluoroacetic Acid SCHEMBL5820047 | 0.93 | HTR6 (0.35) | HTR6MLNRXIAPBIRC2KDM4E | |
| SCHEMBL5803075 | 0.89 | HTR6 (0.43) | HTR6KMT2A | |
| SCHEMBL1062412 | 0.87 | HTR6 (0.44) | HTR6MLNRXIAPBIRC2TSHR | |
| SCHEMBL5820171 | 0.86 | HTR6 (0.41) | HTR6TSHRKMT2A | |
| SCHEMBL1064833 | 0.85 | HTR6 (0.43) | HTR6MLNRKMT2A | |
| Hydrochloric Acid SCHEMBL1059423 | 0.85 | HTR6 (0.42) | HTR6MLNRKMT2A | |
| SCHEMBL5803080 | 0.84 | HTR6 (0.39) | HTR6KDM4EKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060142269-A1 | New compounds | BIOVITRUM AB (SE) | 2006-06-29 | — | — | US | claimed |
| WO-2006062481-A1 | NEW BENZOFURAN DERIVATIVES AND THEIR USE IN THE TREATMENT OF OBESITY, TYPE II DIABETES AND CNS DISORDERS . | BIOVITRUM AB (SE) | 2006-06-15 | — | — | WO | claimed |
| US-20060142269-A1 | New compounds | BIOVITRUM AB (SE) | 2006-06-29 | — | — | US | disclosed |
| WO-2006062481-A1 | NEW BENZOFURAN DERIVATIVES AND THEIR USE IN THE TREATMENT OF OBESITY, TYPE II DIABETES AND CNS DISORDERS . | BIOVITRUM AB (SE) | 2006-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142269-A1 | New compounds | GPR119, GLP1R, IAPP | HTR6 932/4885MLNR 886/4885GLRA3 767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.